ArticleMedicina (Kaunas, Lithuania)2026

First- Versus Second- or Subsequent-Line Use of Cyclin-Dependent Kinase 4/6 Inhibitors for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic or Recurrent Breast Cancer: A Multicenter, Retrospective Cohort Study.

Shoko Yao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.